SLU-PP-332
Stocked in 5mg, 10mg at MontanaPep in Great Falls, Montana. Sold for laboratory research use only.
| Size | Catalog no. | Price per vial |
|---|---|---|
| 5mg | 332a | $40 |
| 10mg | 332b | $80 |
Classification
Synthetic small molecule (NOT a peptide) — pan-agonist of the estrogen-related receptors
Structure and chemistry
SLU-PP-332 is a non-peptidic small organic molecule, chemically a substituted benzohydrazide. This is worth stating plainly because it is frequently and incorrectly catalogued as a peptide: it has no amino acids and no peptide bonds. It is a synthetic ligand for nuclear transcription factors. The “SLU” prefix refers to Saint Louis University, where it was developed.
What the published research shows
The research record is entirely preclinical — cell lines and rodents — and it is genuinely strong within that scope. There are no human trials of any kind. The compound was designed and published explicitly as a chemical probe and in vivo research tool, not as a clinical candidate, and its developers subsequently created a successor compound precisely because SLU-PP-332 lacked oral bioavailability.
Mechanism of action
A pan-agonist of the three estrogen-related receptors, ERR-alpha, ERR-beta and ERR-gamma, with highest potency at ERR-alpha. An important point of confusion: despite the name, estrogen-related receptors are not estrogen receptors and do not bind estrogen — they are orphan nuclear receptors that regulate mitochondrial biogenesis, oxidative phosphorylation, fatty-acid oxidation and the Krebs cycle. SLU-PP-332 activates part of the transcriptional program skeletal muscle normally runs after endurance exercise, including the genes Ddit4 and Slc25a25.
Development history
Developed in the medicinal-chemistry program of Thomas P. Burris, whose laboratory worked on orphan nuclear receptor modulators at Scripps Florida and then at the Center for Clinical Pharmacology at Saint Louis University. It emerged from converting an ERR-beta/gamma-selective agonist into a pan-agonist, work published in 2020, with the characterization of SLU-PP-332 itself published in 2023.
Current regulatory status
SLU-PP-332 is not approved by any regulator anywhere, has never been tested in humans, and is not a peptide. The “exercise in a pill” media framing that followed its 2023 publication substantially outran the evidence — the findings are mouse findings. Analytical laboratories have published metabolite identification methods for SLU-PP-332 and SLU-PP-915. Note also that Thomas Burris holds intellectual property in this area and is a stockholder in companies developing ERR agonists.
Analytical testing
Because this is a small molecule rather than a peptide, peptide-oriented analysis is the wrong tool. Identity and purity should be established by methods appropriate to a small organic compound — typically LC-MS together with NMR against a certified reference standard. A supplier reporting only “HPLC peptide purity” for this compound has applied an inappropriate method.
Ordering from Great Falls
MontanaPep, also known as Montana Peptides, is an independently owned supplier based at 715 13th Ave S, Great Falls, Montana. Local pickup is available by arrangement, and we ship to research addresses across Montana including Billings, Missoula, Bozeman, Helena, Butte, Kalispell and Havre. Call (406) 799-0812 or email customerservice@montanapep.com.